capecitabine has been researched along with pyridoxine in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N | 1 |
| Chang, HM; Chun, YJ; Kang, YK; Kim, MS; Kim, TW; Lee, JL; Lee, SS; Lee, SY; Ryu, MH; Yoon, DH | 1 |
| Chung, HC; Jeung, HC | 1 |
| Chalermchai, T; Sriuranpong, V; Suwanrusme, H; Tantiphlachiva, K; Voravud, N | 1 |
| Ahmad, A; Armstrong, G; Blesing, C; Bond, S; Bulusu, R; Corrie, PG; Daniel, F; Hardy, R; Hill, M; Lao-Sirieix, S; McAdam, K; Moody, AM; Osborne, M; Parashar, D; Wilson, CB; Wilson, G | 1 |
| Endo, I; Ichikawa, Y; Kunisaki, C; Osada, S; Ota, M; Shoichi, F; Suwa, H; Tanaka, K; Tatsumi, K; Watanabe, J; Watanabe, K | 1 |
| Chay, WY; Chia, JWK; Choo, SP; Dent, RA; Koh, KX; Koo, WH; Kwok, LL; Lo, SK; Loh, M; Mok, ZY; Ng, RCH; Soong, RCT; Syn, N; Tan, S; Tham, CK; Toh, HC; Wong, NS; Yap, YS | 1 |
| Hattori, M; Hayashi, T; Iwata, H; Kobayashi, N; Nakada, T; Saito, K; Sawaki, M; Toyama, T; Tsuneizumi, M; Yokota, I; Yoshimura, A | 1 |
| Endo, I; Fujii, S; Ichikawa, Y; Ishibe, A; Oba, MS; Ota, M; Watanabe, J; Watanabe, K | 1 |
| Lian, S; Zhang, X; Zhang, Y; Zhao, Q | 1 |
| Astras, G; Charalambous, A; Filippou, E; Paikousis, L; Tsitsi, T | 1 |
| Franco, PIG; Li, RK; Pandy, JGP | 1 |
| Hung, CH; Kao, YS; Lo, CH; Tu, YK | 1 |
4 review(s) available for capecitabine and pyridoxine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis.
Topics: Antineoplastic Agents; Capecitabine; Hand-Foot Syndrome; Humans; Pyridoxine | 2021 |
Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Topics: Capecitabine; Celecoxib; Hand-Foot Syndrome; Humans; Neoplasms; Pyridoxine; Randomized Controlled Trials as Topic; Sorafenib | 2022 |
Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Hand-Foot Syndrome; Humans; Network Meta-Analysis; Pyridoxine; Randomized Controlled Trials as Topic; Silymarin | 2022 |
8 trial(s) available for capecitabine and pyridoxine
| Article | Year |
|---|---|
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Proportional Hazards Models; Pyridoxine; Syndrome; Treatment Failure; Vitamin B Complex; Young Adult | 2010 |
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Erythema; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Pyridoxine; Vitamin B Complex | 2010 |
A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Placebos; Pyridoxine | 2012 |
The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Japan; Male; Middle Aged; Pyridoxine; Risk Factors; Time Factors; Treatment Failure; Young Adult | 2014 |
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Asian People; Capecitabine; Chi-Square Distribution; Dihydrouracil Dehydrogenase (NADP); Double-Blind Method; Drug Administration Schedule; Female; Folic Acid; Genetic Predisposition to Disease; Genome-Wide Association Study; Hand-Foot Syndrome; Humans; Incidence; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Logistic Models; Male; Membrane Proteins; Microfilament Proteins; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pyridoxine; Risk Assessment; Risk Factors; Severity of Illness Index; Singapore; Time Factors; Treatment Outcome | 2017 |
A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Topics: Aged; Breast Neoplasms; Capecitabine; Female; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyridoxine | 2018 |
The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Therapy, Combination; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Negative Results; Pharmaceutical Preparations; Phytotherapy; Plant Extracts; Pyridoxine; Young Adult | 2020 |
A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Topics: Activities of Daily Living; Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Capecitabine; Double-Blind Method; Doxorubicin; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Pilot Projects; Polyethylene Glycols; Pyridoxine; Quality of Life; Treatment Outcome; Vitamin B Complex | 2021 |
3 other study(ies) available for capecitabine and pyridoxine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged; Neoplasm Metastasis; Pyridoxine; Retrospective Studies; Vitamin B Complex | 2010 |
Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erythema; Fluorouracil; Foot; Hand; Humans; Pyridoxine; Syndrome; Vitamin B Complex | 2010 |